Wockhardt LimitedNSE: WOCKPHARMA

Press Release Dec 11 2023

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The study demonstrated that a three-day treatment with Nafithromycin is as effective as a seven-day treatment with Moxifloxacin, showing a high clinical cure rate. The study reported no serious adverse events, indicating that Nafithromycin is safe for community use against resistant organisms.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873.".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases